Bayer Opens a Second Front: Tariff Bid on Chinese Glyphosate Follows Supreme Court Victory
04.07.2026 - 03:04:12 | boerse-global.de
Bayer’s script changed faster than investors had anticipated. No sooner had the Supreme Court handed the group a landmark legal reprieve than management pivoted to an aggressive new offensive: a formal request for anti-dumping duties on Chinese glyphosate imports. The application, filed on June 30, 2026, with the U.S. Department of Commerce and the International Trade Commission, pits the Leverkusen-based giant against the very farmers it depends on for revenue.
The move, orchestrated by Bayer’s newly established U.S. subsidiary Ruveon, aims to shield the core glyphosate business from a flood of cheap generics out of China. CEO Bill Anderson had previously warned that U.S. production could be at risk without trade protection. Yet the tariff gambit carries its own peril. Major American agricultural groups—including the National Corn Growers Association and the American Soybean Association—have already mobilised in opposition, arguing that higher import costs will squeeze farm margins and inflate input prices.
The timing is striking. Only days earlier, a separate court decision had capped a contentious glyphosate verdict at $1.25 million, providing a welcome dose of certainty after years of litigation that had cost Bayer over $10 billion. That capped ruling, combined with the Supreme Court’s 7-2 judgment in late June—which held that consumers cannot sue Bayer over missing cancer warnings where the EPA has not required them—appeared to draw a line under the legal morass.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer’s response was to reorganise its American glyphosate operations. Ruveon, headquartered in St. Louis, Missouri, now consolidates all U.S. glyphosate activities under one roof. Formerly part of the broader Bayer crop science division, the unit gains independent control over production, logistics and pricing. Alfonso Alba Ordóñez, appointed CEO of Ruveon, will also steer marketing of the flagship Roundup brand to U.S. agricultural customers. Although Ruveon remains fully owned by Bayer, its structural autonomy is designed to increase agility in a market dominated by copycat products.
Investors have so far focused on the legal relief rather than the emerging trade tensions. Shares closed at €53.22 on Friday, within a whisker of the 52-week high touched at €53.28. Over the past twelve months the stock has soared more than 104%, and the year-to-date gain stands at 40.1%. The euphoria is reflected in the relative strength index, which has hit 85.3—a level that typically signals severe overbought conditions. The stock now trades 43.6% above its 200-day moving average, while annualised volatility of 63.2% underscores the sensitivity of the share price to any fresh glyphosate-related development.
Deutsche Bank has responded to the brighter legal outlook by lifting its price target from €45 to €60 and upgrading the stock to “Buy”. Analyst Virginie Boucher-Ferte argues that existing provisions are adequate to cover the remaining litigation, and that legal risk is increasingly discounted in the current valuation.
The next inflection point arrives on August 19, when a U.S. court is scheduled to deliver a final ruling on the multi-billion-dollar glyphosate class-action settlement. Between now and then, Ruveon must demonstrate that its operational independence can deliver real competitive gains—while Bayer simultaneously navigates a tariff application that tests the loyalty of its most important customer base. The market is cheering the end of one war, but the next one has already begun.
Ad
Bayer Stock: New Analysis - 4 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
